O’Malley, David M.
Calo, Corinne A.
Article History
Accepted: 30 April 2021
First Online: 14 June 2021
Declarations
:
: David M. O'Malley has received institutional support for clinical trials from AstraZeneca, Tesaro/GlaxoSmithKline, ImmunoGen, Janssen/Johnson & Johnson, AbbVie, Regeneron, Amgen, Novocure, Genentech/Roche, VentiRx, Array BioPharma, EMD Serono, Ergomed, Ajinomoto, Inc., Ludwig Cancer Research, Stemcentrx, Inc., Cerulean Pharma, Gynecologic Oncology Group (GOG) Foundation, Bristol-Myers Squibb, Serono, Inc., TRACON Pharmaceuticals, Yale University, New Mexico Cancer Care Alliance, INC Research, Inc., inVentiv Health Clinical, Iovance Biotherapeutics, Inc., PRA International, Eisai, Agenus, Merck, Genmab, Seagen, Mersana Therapeutics, and Clovis Oncology; and has received compensation for service as a consultant/advisory board participant from AstraZeneca, Tesaro/GlaxoSmithKline, ImmunoGen, Ambry, Janssen/Johnson & Johnson, AbbVie, Regeneron, Amgen, Novocure, Genentech/Roche, GOG Foundation, Iovance Biotherapeutics, Myriad Genetics, Eisai, Agenus, Tarveda, Merck, Seagen, Novartis, Mersana Therapeutics, Clovis Oncology, Rubius Therapeutics, and Elevar Therapeutics. Corinne A. Calo declares that she has no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.